TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02721082
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
Study: NCT01391221
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Study: NCT02925611
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02925611
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02778100
Drug: Nasal Glucagon
Normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intranasally.
Study: NCT02778100
Drug: Oxymetazoline
Normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intranasally.
Study: NCT00825266
Drug: bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
Study: NCT00825266
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
Study: NCT01831622
Drug: Ritalin
Normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
Study: NCT00236873
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04881006
Drug: Dapagliflozin 10 mg tablets
Normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Study: NCT01811082
Drug: Coenzyme A
Normalized name: Coenzyme A
DrugBank: Coenzyme A (DB01992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme A 400mg per day.
Study: NCT01811082
Drug: Pantethine
Normalized name: Pantethine
DrugBank: Pantethine (DB11190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantethine 600mg per day.
Study: NCT00553696
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Study: NCT00553696
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 80 mg/m2 on days 1-21 of each 28 day cycle
Study: NCT00553696
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Study: NCT01054768
Drug: alpha-lipoic acid and acetyl-L-carnitine
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: none to report
Study: NCT01054768
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: none to report
Study: NCT00671931
Drug: low dexmedetomidine, low propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
Study: NCT00671931
Drug: high dexmedetomidine, low propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
Study: NCT00671931
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
Study: NCT00671931
Drug: Dexmedetomidin
Normalized name: Dexmedetomidin
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
Study: NCT00671931
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
Study: NCT02616874
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
Study: NCT01485042
Drug: Pazopanib and TH-302
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
Study: NCT01951638
Drug: Vericiguat (BAY1021189) (1.25 mg)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg BAY1021189 tablets
Study: NCT01951638
Drug: Vericiguat (BAY1021189) (5 mg)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg BAY1021189 tablets
Study: NCT02382068
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via intratympanic injection
Study: NCT02382068
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum
Study: NCT02660866
Drug: Vorapaxar 2.08 mg/d + background APT + SMT.
DrugBank: Vorapaxar (DB09030)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study: NCT06733506
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml).
Study: NCT01517412
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study: NCT01393782
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
Study: NCT02173548
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04657744
Drug: Gilenya
Normalized name: Gilenya
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 capsule contains 0.5 mg Fingolimod
Study: NCT00993655
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
Study: NCT00993655
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 intraperitoneal day 1
Study: NCT00993655
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
Study: NCT00549757
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg film-coated tablets
Study: NCT03395405
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 500 mg tablet twice daily with food for 56 consecutive doses
Study: NCT00743769
Drug: thymosin beta 4
Normalized name: Thymosin beta 4
DrugBank: Thymosin beta-4 (DB12003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
Study: NCT03496506
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
Study: NCT03496506
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each film-coated tablet containing 75 mg of clopidogrel (oral use)
Study: NCT01517412
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To be kept at stable dose (≥1.5 g/day) throughout the study.
Study: NCT00778128
Drug: CP-4126
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
Study: NCT00778128
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
Study: NCT00258258
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00656084
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
Study: NCT00656084
Drug: mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan.
Study: NCT02641392
Drug: GED-0301
Normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mongersen
Study: NCT03197012
Drug: 90Y-DOTA-TOC
Normalized name: DOTA-TATE
DrugBank: Edotreotide yttrium Y-90 (DB17160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
Study: NCT03197012
Drug: 68Ga-DOTA-TOC
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
Study: NCT00656084
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan.
Study: NCT03775200
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-finding
Study: NCT00002611
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002611
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02335203
Drug: Depot medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
Study: NCT01619059
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
Study: NCT03026790
Drug: Buprenorphine-Naloxone
Normalized name: Buprenorphine-Naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
Study: NCT00198484
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00687999
Drug: pegylated interferon alpha and ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard pegylated interferon alpha and ribavirin
Study: NCT04329000
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-demand Esomeprazole 40 mg QD
Study: NCT04329000
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Esomeprazole 40 mg QD
Study: NCT01494987
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine tablet(s) administered orally
Study: NCT02398929
Drug: Bisoprolol 2.5 mg
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol 2.5 mg will be given once daily
Study: NCT01619059
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Study: NCT01619059
Drug: Metformin IR
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
Study: NCT01619059
Drug: Placebo matching with Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
Study: NCT01335867
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin escalated to 3 grams daily for 8 weeks
Study: NCT01494987
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
Study: NCT02565914
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT01250652
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg levocetirizine for 5 days
Study: NCT01250652
Drug: Levocetirizine plus Hydroxyzine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
Study: NCT00105209
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00105209
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04297293
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
Study: NCT00198094
Drug: Sertraline and Alprazolam XR
Normalized name: alprazolam Extended Release Oral Tablet
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02394418
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of delirium by inhaled sevoflurane
Study: NCT02394418
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of delirium by propofol i.v. infusion
Study: NCT02394418
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of delirium by dexmedetomidine i.v. infusion
Study: NCT02642250
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
Study: NCT00002587
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002587
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00644631
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
Study: NCT01578811
Drug: SK-MS10
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage
Study: NCT00778583
Drug: Nitrofurantoin 100 mg capsules
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01787448
Drug: Topical gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study: NCT01787448
Drug: Sodium lauryl sulfate 0.1%
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study: NCT01787448
Drug: Sodium chloride solution 0.9% (saline)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study: NCT03546894
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brigatinib tablets.
Study: NCT03546894
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib capsules.
Study: NCT03546894
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib capsules.
Study: NCT03546894
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib capsules.
Study: NCT01009918
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01094925
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 300mg gabapentin
Study: NCT01094925
Drug: Gabapentin 600mg
Normalized name: GABAPENTIN 600MG TAB
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 600mg gabapentin
Study: NCT01371526
Drug: depot tetracosactide
Normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg, 3x weekly by sc injection
Study: NCT04771026
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
Study: NCT00162526
Drug: Tocopherol
Normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03588611
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Study: NCT03588611
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;